

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-2. (Canceled)

3. (Currently amended) An isolated anti-glypican 3 antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively.

4-5. (Canceled)

6. (Currently amended) An isolated anti-glypican 3 antibody selected from the group consisting of the antibody of any one of (1) - (7):

(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92; and

(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

7. (Previously presented) The antibody as claimed in claim 3 or 6, which is a humanized antibody.

8-15. (Canceled)

16. (Currently amended) An isolated monoclonal antibody capable of binding to an epitope of glypican 3 to which a second antibody is capable of binding, wherein said second antibody comprises a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively.

17-18. (Canceled)

19. (Withdrawn) A polynucleotide coding for a heavy chain variable region or a light chain variable region of the antibody as claimed in claim 7 or 8.

20. (Withdrawn) The polynucleotide as claimed in Claim 19 having the sequence set forth in any one of SEQ ID NOs: 11-21, 33-43, 55-59, 65-70 and 77-83.

21. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 3.

22. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 6.

23. (Canceled)

24. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 524 - 563 of glypican 3.

25. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 537 - 563 of glypican 3.

26. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 544 - 553 of glypican 3.

27. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 546 - 551 of glypican 3.

28. (Canceled)

29. (Currently amended) An isolated anti-glypican 3 antibody comprising any one of (1) - (15) below:

(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 174, 144 and 158, respectively;

(2) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 175, 144 and 158, respectively;

(3) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 176, 144 and 158, respectively;

(4) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 177, 144 and 158, respectively;

(5) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 178, 144 and 158, respectively;

(6) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 179, 144 and 158, respectively;

(7) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable

region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 180, 144 and 158, respectively;

(8) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 181, 144 and 158, respectively;

(9) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 182, 144 and 158, respectively;

(10) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 183, 144 and 158, respectively;

(11) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 184, 144 and 158, respectively;

(12) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 185, 144, and 158, respectively;

(13) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 186, 144 and 158, respectively;

(14) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable

region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 187, 144 and 158, respectively; and

(15) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 188, 144 and 158, respectively.

30-31. (Canceled)

32. (Currently amended) The antibody as claimed in ~~any one of claims 14, 16, and 29,~~
claim 16 or 29, which is a human antibody.

33-37. (Canceled)

38. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 16.

39. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 29.

40. (Canceled)

41. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 32.

42-46. (Canceled).

47. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 7.

48-53. (Canceled)

54. (New) The antibody of claim 6, wherein the antibody is:

(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

55. (New) A pharmaceutical composition comprising the antibody as claimed in claim 54.

56. (New) The antibody of claim 6, wherein the antibody is:

(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

57. (New) A pharmaceutical composition comprising the antibody as claimed in claim 56.

58. (New) The antibody of claim 6, wherein the antibody is:

(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

59. (New) A pharmaceutical composition comprising the antibody as claimed in claim 58.

60. (New) The antibody of claim 6, wherein the antibody is:

(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

61. (New) A pharmaceutical composition comprising the antibody as claimed in claim 60.

62. (New) The antibody of claim 6, wherein the antibody is:

(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

63. (New) A pharmaceutical composition comprising the antibody as claimed in claim 62.

64. (New) The antibody of claim 6, wherein the antibody is:

(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

65. (New) A pharmaceutical composition comprising the antibody as claimed in claim 64.

66. (New) The antibody of claim 6, wherein the antibody is:

(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

67. (New) A pharmaceutical composition comprising the antibody as claimed in claim 66.

68. (New) The antibody of claim 29, wherein the antibody comprises:

(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 174, 144 and 158, respectively.

69. (New) A pharmaceutical composition comprising the antibody as claimed in claim 68.

70. (New) The antibody of claim 29, wherein the antibody comprises:

(2) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 175, 144 and 158, respectively.

71. (New) A pharmaceutical composition comprising the antibody as claimed in claim 70.

72. (New) The antibody of claim 29, wherein the antibody comprises:

(3) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 176, 144 and 158, respectively.

73. (New) A pharmaceutical composition comprising the antibody as claimed in claim 72.

74. (New) The antibody of claim 29, wherein the antibody comprises:

(4) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 177, 144 and 158, respectively.

75. (New) A pharmaceutical composition comprising the antibody as claimed in claim 74.

76. (New) The antibody of claim 29, wherein the antibody comprises:

(5) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 178, 144 and 158, respectively.

77. (New) A pharmaceutical composition comprising the antibody as claimed in claim 76.

78. (New) The antibody of claim 29, wherein the antibody comprises:

(6) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 179, 144 and 158, respectively.

79. (New) A pharmaceutical composition comprising the antibody as claimed in claim 78.

80. (New) The antibody of claim 29, wherein the antibody comprises:

(7) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 180, 144 and 158, respectively.

81. (New) A pharmaceutical composition comprising the antibody as claimed in claim 80.

82. (New) The antibody of claim 29, wherein the antibody comprises:

(8) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 181, 144 and 158, respectively.

83. (New) A pharmaceutical composition comprising the antibody as claimed in claim 82.

84. (New) The antibody of claim 29, wherein the antibody comprises:

(9) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 182, 144 and 158, respectively.

85. (New) A pharmaceutical composition comprising the antibody as claimed in claim 84.

86. (New) The antibody of claim 29, wherein the antibody comprises:

(10) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 183, 144 and 158, respectively.

87. (New) A pharmaceutical composition comprising the antibody as claimed in claim 86.

88. (New) The antibody of claim 29, wherein the antibody comprises:

(11) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 184, 144 and 158, respectively.

89. (New) A pharmaceutical composition comprising the antibody as claimed in claim 88.

90. (New) The antibody of claim 29, wherein the antibody comprises:

(12) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 185, 144, and 158, respectively.

91. (New) A pharmaceutical composition comprising the antibody as claimed in claim 90.

92. (New) The antibody of claim 29, wherein the antibody comprises:

(13) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 186, 144 and 158, respectively.

93. (New) A pharmaceutical composition comprising the antibody as claimed in claim 92.

94. (New) The antibody of claim 29, wherein the antibody comprises:

(14) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 187, 144 and 158, respectively.

95. (New) A pharmaceutical composition comprising the antibody as claimed in claim 94.

96. (New) The antibody of claim 29, wherein the antibody comprises:

(15) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 188, 144 and 158, respectively.

97. (New) A pharmaceutical composition comprising the antibody as claimed in claim 96.